购物车
您的购物车当前为空
Setipiprant (ACT-129968) 是一种口服的选择性 CRTH2 拮抗剂,IC50为6.0 nM。
别名 塞替匹仑, KYTH-105, ACT-129968
Setipiprant (ACT-129968) 是一种口服的选择性 CRTH2 拮抗剂,IC50为6.0 nM。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 132 | 现货 | |
| 5 mg | ¥ 198 | 现货 | |
| 10 mg | ¥ 278 | 现货 | |
| 25 mg | ¥ 446 | 现货 | |
| 50 mg | ¥ 693 | 现货 | |
| 100 mg | ¥ 1,090 | 现货 | |
| 200 mg | ¥ 1,560 | 待询 | |
| 1 mL x 10 mM (in DMSO) | ¥ 253 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。

| 产品描述 | Setipiprant (ACT-129968) is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells. |
| 靶点活性 | CRTH2:6.0 nM, EP2:2600 nM, DP1 (human):1290 nM |
| 别名 | 塞替匹仑, KYTH-105, ACT-129968 |
| 分子量 | 402.42 |
| 分子式 | C24H19FN2O3 |
| CAS No. | 866460-33-5 |
| Smiles | C(C(O)=O)N1C2=C(C=3C1=CC=C(F)C3)CN(C(=O)C=4C5=C(C=CC4)C=CC=C5)CC2 |
| 密度 | 1.37 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 45 mg/mL (111.82 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.97 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多